# CTO1681

Source: https://onco.cc/drugs/cto1681/  
OnCo record `cto1681` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CTO1681 is a tablet from CytoAgents meant to prevent and treat cytokine release syndrome, an immune over-reaction that can follow CAR-T cell therapy for blood cancers.

## Summary

CTO1681 is CytoAgents' oral anti-inflammatory compound. ClinicalTrials.gov lists NCT05905328, a phase 1/2 study sponsored by CytoAgents of CTO1681 for the prevention and treatment of cytokine release syndrome in patients receiving CAR T-cell therapy, as recruiting. A 2026 National Cancer Institute SBIR award to CytoAgents extends the work to people with multiple myeloma receiving CAR T-cell therapy. It is a supportive medicine: it is not meant to treat the cancer itself.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-04
- Also known as: GP1681
- Tags: pipeline
- Code: CTO1681
- Modality: Oral small molecule
- Mechanism: Described by CytoAgents as a steroid-sparing inhibitor of prostaglandin and prostacyclin-mediated inflammation, given by mouth to damp the cytokine surge of cytokine release syndrome.

## Sources

- ClinicalTrials.gov: NCT05905328: https://clinicaltrials.gov/study/NCT05905328
- NIH RePORTER: award 5R44CA295189-02: https://reporter.nih.gov/project-details/11418976

## Connected records

- companies: [CytoAgents](https://onco.cc/companies/cytoagents/)
- terms: [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/)

---
JSON: https://onco.cc/api/v1/entities/cto1681.json